[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Universitas Padjadjaran\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":463},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,18,0,[8,42,69,92,115,138,166,198,219,244,266,288,315,338,365,388,413,435],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":41},"100630952","effects-of-dual-task-oriented-circuit-training-on-walking-recovery-in-sub-acute-stroke-100630952",false,"NCT07494357","Effects of Dual Task-Oriented Circuit Training on Walking Recovery in Sub-acute Stroke","The Effect of Dual Task-Oriented Circuit Training on Neuroplasticity and Walking Adaptability in Subacute Stroke Patients: A Pilot and Feasibility Study","DTOCT-Stroke","Inclusion Criteria\n\n1. Diagnosed with a first-ever subacute stroke (defined as 2 weeks to 5 months post-onset) with anterior circulation involvement.\n2. Diagnosis confirmed via neuroimaging (CT or MRI).\n3. Men and women aged 40 to 65 years.\n4. Motor recovery in the lower limbs corresponding to Brunnstrom stages 4 to\n5. Functional Ambulation Category (FAC) score of at least grade 3.\n6. Ability to walk independently, with or without walking aids.\n7. Montreal Cognitive Assessment Indonesian version (MoCA-INA) score of ≥20, demonstrating the capacity to collaborate and follow multi-step instructions.\n8. Medically stable with controlled comorbidities.\n\nExclusion Criteria\n\n1. Expressive or receptive aphasia that impedes task comprehension\n2. Unstable cardiovascular or medical conditions (e.g., severe hypertension, congestive heart failure) for which moderate exercise is contraindicated.\n3. Moderate to severe depression, indicated by a Patient Health Questionnaire-9 (PHQ-9) score of ≥ 15.","ALL","40 Years","65 Years",{"count":21,"type":22},36,"ESTIMATED","INTERVENTIONAL",[25],"NA","This pilot study aims to assess the feasibility, safety, and initial efficacy of an integrated Dual Task-Oriented Circuit Training (DTOCT) program for individuals in the subacute phase of stroke recovery. Although numerous patients recover the capacity to walk in a regulated hospital environment, they frequently encounter difficulties with \"community ambulation,\" the capability to traverse real-world settings while multitasking (e.g., walking while conversing or circumventing barriers). This study will examine if the integration of high-intensity circuit training with cognitive difficulties can promote neuroplasticity and enhance the patient's capacity to safely traverse intricate daily settings.",[28],"Stroke, Cerebrovascular","NOT_YET_RECRUITING","2026-05-23",{"date":32,"type":33},"2026-05-28","ACTUAL",{"date":35,"type":22},"2026-06-01",{"date":37,"type":22},"2026-08-30",{"name":39,"class":40},"Universitas Padjadjaran","OTHER",1,{"id":43,"slug":44,"hasResults":11,"nctId":45,"briefTitle":46,"officialTitle":47,"acronym":4,"eligibilityCriteria":48,"healthyVolunteers":11,"sex":17,"minAge":49,"maxAge":50,"enrollmentInfo":51,"targetDuration":4,"studyType":53,"phases":4,"briefSummary":54,"conditions":55,"keywords":4,"overallStatus":60,"whyStopped":4,"lastUpdateSubmitDate":61,"lastUpdatePostDateStruct":62,"startDateStruct":64,"completionDateStruct":66,"leadSponsor":68,"locationsCount":41},"100627689","tb-type-and-spirometry-result-vs-functional-capacity-based-on-6mwt-in-people-with-post-tb-lung-disease-100627689","NCT07451899","TB Type and Spirometry Result vs. Functional Capacity Based on 6MWT in People With Post-TB Lung Disease","Correlation Between Types of Tuberculosis, Spirometry Result, and Functional Capacity Based on the 6-Minute Walk Test (6MWT) in Adolescents With Post-Tuberculosis Lung Disease.","Inclusion Criteria:\n\n* Adolescents (10-18 year old)\n* Diagnosed with post tuberculosis lung disease by pediatrician\n* Capable of performing the 6MWT\n\nExclusion Criteria:\n\n* Diagnosed with another lung disease\n* Having physical limitations that hinder the 6MWT","10 Years","18 Years",{"count":52,"type":22},20,"OBSERVATIONAL","Post-Tuberculosis Lung Disease (PTLD) is defined as chronic respiratory impairment due to previous pulmonary TB. Children recovering from pulmonary TB undergo ongoing respiratory health challenges, including more frequent respiratory symptoms, reduced lung volumes, and a threefold higher rate of pulmonary dysfunction compared to healthy children. These conditions could lead to long-term health consequences such as difficulties in performing daily activities. Pulmonary function impairment in PTLD includes approximately 10% of patients losing more than 50% of lung function. Adolescents who have undergone TB treatment often experience pulmonary function impairment and reduced physical capacity. This aims of this study is to analyze the correlation between type of tuberculosis, spirometry result, and functional capacity in adolescents with post-tuberculosis lung disease.\n\nThis study is an analytical observational study with a cross-sectional approach. This study is conducted at Department of Physical Medicine and Rehabilitation, Hasan Sadikin Hospital, Bandung, starting in March until May 2026. Inclusion criteria including: adolescents (10-18 year old), and diagnosed with post tuberculosis lung disease by pediatrician, and capable of performing the 6MWT. The participants with post TB lung disease will undergo spirometry and functional capacity assessment using the 6-minute walk test (6MWT). Outcomes include spirometry result and functional capacity using 6MWT.",[56,57,58,59],"Post Tuberculosis","Lung Disease","Functional Capacity","Spirometry","RECRUITING","2026-05-09",{"date":63,"type":33},"2026-05-12",{"date":65,"type":33},"2026-03-01",{"date":67,"type":22},"2026-05-31",{"name":39,"class":40},{"id":70,"slug":71,"hasResults":11,"nctId":72,"briefTitle":73,"officialTitle":74,"acronym":4,"eligibilityCriteria":75,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":76,"enrollmentInfo":77,"targetDuration":4,"studyType":23,"phases":79,"briefSummary":80,"conditions":81,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":84,"lastUpdatePostDateStruct":85,"startDateStruct":87,"completionDateStruct":89,"leadSponsor":91,"locationsCount":4},"100634460","effect-of-inspiratory-muscle-training-on-diaphragm-function-in-copd-patients-100634460","NCT07539974","Effect of Inspiratory Muscle Training on Diaphragm Function in COPD Patients","Effect of Threshold Inspiratory Muscle Training on Diaphragm Thickness and Diaphragm Excursion Value in Chronic Obstructive Pulmonary Disease Patients","Inclusion Criteria:\n\n* Patients with a COPD GOLD stage 2\n* Age 40-59 years\n* Maximal Inspiratory Pressure (MIP) value of less than 70 cmH₂O or below the lower limit of normal for their age and gender\n* Clinically stable for at least 4 weeks prior to the study\n* Ready to participate in research and sign informed consent\n\nExclusion Criteria:\n\n* Patients with contraindications to Inspiratory Muscle Training or spirometry (e.g., recent thoracic or abdominal surgery, pneumothorax, or history of spontaneous pneumothorax).\n* Patients participating in other structured respiratory muscle training or pulmonary rehabilitation programs concurrently that could confound the results\n* Patients undergoing other therapies that may affect diaphragmatic muscle measurement results, such as electrical diaphragmatic stimulation","59 Years",{"count":78,"type":22},15,[25],"This study investigates the effect of threshold inspiratory muscle training on diaphragm thickness and diaphragm excursion, measured using ultrasonography, in patients with stable chronic obstructive pulmonary disease (COPD).",[82,83],"Chronic Obstructive Pulmonary Disease (COPD)","Diaphragm Dysfunction","2026-04-20",{"date":86,"type":33},"2026-04-23",{"date":88,"type":22},"2026-04-01",{"date":90,"type":22},"2026-09-01",{"name":39,"class":40},{"id":93,"slug":94,"hasResults":11,"nctId":95,"briefTitle":96,"officialTitle":97,"acronym":4,"eligibilityCriteria":98,"healthyVolunteers":11,"sex":17,"minAge":50,"maxAge":76,"enrollmentInfo":99,"targetDuration":4,"studyType":23,"phases":101,"briefSummary":102,"conditions":103,"keywords":105,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":107,"lastUpdatePostDateStruct":108,"startDateStruct":110,"completionDateStruct":112,"leadSponsor":114,"locationsCount":41},"100631884","effect-of-immersive-virtual-reality-cognitive-rehabilitation-on-subacute-stroke-patients-a-pilot-study-100631884","NCT07506486","Effect of Immersive Virtual Reality Cognitive Rehabilitation on Subacute Stroke Patients (A Pilot Study)","Effect of Cognitive Rehabilitation Using Immersive Virtual Reality on Cognitive Function and Functional Activity of Subacute Stroke Patients: A Pilot Randomized Controlled Trial","Inclusion Criteria:\n\n* Male or female aged 40-59 years old\n* Stroke patient 2-4 months onset of stroke\n* Burnstorm stage V or above\n* First-time stroke that has been diagnosed by a neurologist with CT scan and\u002For MRI\n* Stroke risk factors and comorbidities are controlled with medication\n* Mild and moderate level of cognitive impairment based on MOCA and can use devices\n* Participants can grip and operate VR console with their hand\n* Participants can follow instructions and exercises\n* Participants were cooperative and willing to participate in the study by signing a consent form after receiving an explanation.\n\nExclusion Criteria:\n\n* Participants with severe cognitive impairment or aphasia struggle to understand instructions\n* Neglected patient\n* Participants with low vision unable to perceive content on screens\n* Participant with eyestrain characterized by blurring vision, dry eyes, foreign body sensation, itching watering, neck stiffness and backache\n* Severe musculoskeletal disorders causing problem in standing and following instruction",{"count":100,"type":22},22,[25],"This pilot randomized controlled trial aims to evaluate the effectiveness of cognitive rehabilitation using an immersive Virtual Reality (VR) system compared to conventional paper-and-pencil cognitive training in subacute stroke patients. A total of 22 participants will be randomly assigned to either the VR intervention group (n=11) or the conventional control group (n=11). The study will measure changes in cognitive function and functional independence",[104],"Stroke (Subacute)",[106],"cognitive impairment","2026-03-31",{"date":109,"type":33},"2026-04-06",{"date":111,"type":22},"2026-04-15",{"date":113,"type":22},"2026-09-30",{"name":39,"class":40},{"id":116,"slug":117,"hasResults":11,"nctId":118,"briefTitle":119,"officialTitle":120,"acronym":4,"eligibilityCriteria":121,"healthyVolunteers":122,"sex":17,"minAge":123,"maxAge":76,"enrollmentInfo":124,"targetDuration":4,"studyType":23,"phases":125,"briefSummary":126,"conditions":127,"keywords":4,"overallStatus":60,"whyStopped":4,"lastUpdateSubmitDate":130,"lastUpdatePostDateStruct":131,"startDateStruct":133,"completionDateStruct":135,"leadSponsor":137,"locationsCount":41},"100628923","comparative-effectiveness-of-long-pulsed-1064-nm-ndyag-and-fractional-co-laser-in-skin-rejuvenation-100628923","NCT07467954","Comparative Effectiveness of Long-Pulsed 1064-nm Nd:YAG and Fractional CO₂ Laser in Skin Rejuvenation","A Comparative Split-Face Study of Long-Pulsed 1064-nm Nd:YAG and Fractional CO₂ Laser for Skin Rejuvenation Based on Dermal Thickness, Skin Elasticity, Wrinkle Assessment, and Global Aesthetic Improvement Scale Scores","Inclusion Criteria:\n\n* Male and female patients with skin aging classified as Glogau scale II-III\n* Age 30-59 years.\n\nExclusion Criteria:\n\n* Pregnant or breastfeeding women.\n* Active smokers.\n* Individuals with high levels of sun exposure.\n* History of facial laser therapy, microdermabrasion, chemical peeling, botulinum toxin injection, microneedling, or skin booster injections within the past six months.\n* Use of oral isotretinoin within the past six months.\n* Use of topical retinoids or their derivatives, topical vitamin C, or other collagen-stimulating and skin-rejuvenating agents within the past two weeks.\n* Use of oral vitamin C, collagen-stimulating supplements, antioxidants, or hormone therapy with skin-rejuvenating effects within the past one month.\n* Presence of active facial skin inflammation.\n* History of keloid formation.\n* History of allergy to topical lidocaine anesthesia.",true,"30 Years",{"count":78,"type":22},[25],"Skin rejuvenation is an effort to improve skin condition from the signs of skin aging. Skin aging is a complex biological process influenced by intrinsic and extrinsic factors, leading to changes in the epidermis and dermis, including decreased collagen characterized by dermal thinning, as well as alterations in skin appearance such as laxity and wrinkles. Laser therapy is one of the treatment modalities for skin rejuvenation, aiming to induce neocollagenesis and collagen remodeling, resulting in dermal thickening and improvement in skin appearance. Fractional CO₂ laser is an ablative laser considered the gold standard therapy for skin rejuvenation, whereas Long Pulsed (LP) Nd:YAG 1064 nm is a nonablative laser that is also used for skin rejuvenation. To date, there have been no studies evaluating the comparative effectiveness between fractional CO₂ laser and LP Nd:YAG 1064 nm for skin rejuvenation. Therefore, research comparing the effectiveness of fractional CO₂ laser and LP Nd:YAG 1064 nm for skin rejuvenation is needed, assessed based on dermal thickness, skin elasticity, wrinkles, and Global Aesthetic Improvement Scale scores.",[128,129],"Skin Rejuvenation","Laser","2026-03-08",{"date":132,"type":33},"2026-03-12",{"date":134,"type":33},"2025-10-14",{"date":136,"type":22},"2026-04-16",{"name":39,"class":40},{"id":139,"slug":140,"hasResults":11,"nctId":141,"briefTitle":142,"officialTitle":143,"acronym":144,"eligibilityCriteria":145,"healthyVolunteers":11,"sex":17,"minAge":146,"maxAge":4,"enrollmentInfo":147,"targetDuration":4,"studyType":23,"phases":149,"briefSummary":150,"conditions":151,"keywords":153,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":158,"lastUpdatePostDateStruct":159,"startDateStruct":161,"completionDateStruct":163,"leadSponsor":165,"locationsCount":41},"100615503","evaluation-and-demonstration-of-new-tuberculosis-diagnostics-for-indonesia-100615503","NCT07293455","Evaluation and Demonstration of New Tuberculosis Diagnostics for Indonesia","Evaluation and Demonstration of New Tuberculosis Diagnostics for Indonesia; Work Package 3: Cluster Randomised Controlled Trial of A Diagnostic Package to Increase the Number of Tuberculosis Cases Notified","EVIDENT","Inclusion Criteria:\n\n1. Aged between \\>28 days and 14 years old with the following symptoms:\n\n   * Cough ≥2 weeks\n   * Acute malnutrition\n   * Weight loss or weight faltering during the past 3 months among those who had contact history with patients with TB in the past 12 months.\n2. Aged ≥15 years old who had a cough for ≥2 weeks or bloody cough, with or without the following symptoms:\n\n   * Cough with\u002Fwithout sputum\n   * Fever\n   * Weight loss\n   * Night sweat\n   * Fatigue\n   * Chest pain\u002Fdiscomfort\n   * Breathlessness\n   * Loss of appetite\n   * Shivering\n\nExclusion Criteria:\n\n* Have started TB treatment or TB prophylaxis therapy.","29 Days",{"count":148,"type":22},40000,[25],"The goal of this cluster-randomised controlled trial (CRCT) is to learn whether the use of new non-sputum-based diagnostic tests and other intervention components for tuberculosis (TB) diagnosis in healthcare facilities (HCF) can increase TB notifications. The main questions it aims to answer are: (1) Does the diagnostic intervention package raise TB notifications by HCF?; (2) Does the diagnostic intervention package raise the proportion of patients with TB who are diagnosed with microbiological tests, lower the time needed for TB diagnosis, lower the number of visits to HCF before TB diagnosis, raise the use of TB tests by healthcare providers, and lower the costs for TB diagnosis?\n\nResearchers will compare the diagnostic intervention package provided to HCFs and the community in the intervention arm with the standard of care in the control arm to assess the intervention's effect. Healthcare providers will be trained to provide diagnostic interventions to patients visiting their HCFs and to community residents in the areas surrounding HCFs.",[152],"Tuberculosis",[152,154,155,156,157],"Diagnosis","Tongue swab","Near point-of-care test","Cluster randomised controlled trial","2026-02-06",{"date":160,"type":33},"2026-02-10",{"date":162,"type":22},"2026-03",{"date":164,"type":22},"2027-10",{"name":39,"class":40},{"id":167,"slug":168,"hasResults":11,"nctId":169,"briefTitle":170,"officialTitle":171,"acronym":172,"eligibilityCriteria":173,"healthyVolunteers":11,"sex":174,"minAge":50,"maxAge":175,"enrollmentInfo":176,"targetDuration":4,"studyType":23,"phases":178,"briefSummary":181,"conditions":182,"keywords":188,"overallStatus":60,"whyStopped":4,"lastUpdateSubmitDate":191,"lastUpdatePostDateStruct":192,"startDateStruct":194,"completionDateStruct":196,"leadSponsor":197,"locationsCount":41},"100607040","phase-1-msc-exosome-therapy-for-post-preeclampsia-endothelial-dysfunction-100607040","NCT07183384","MSC Exosome Therapy for Post-Preeclampsia Endothelial Dysfunction","The Effectiveness of Mesenchymal Stem Cell-Derived Exosome Therapy in Improving Endothelial Dysfunction in Postpartum Mothers With a History of Preeclampsia","EXITPE","Inclusion Criteria:\n\n* Postpartum\n* Confirmed diagnosis of preeclampsia in the last pregnancy\n* Postpartum period of first week and second week\n* Able to provide informed consent\n\nExclusion Criteria:\n\n* History of chronic hypertension prior to pregnancy\n* Major cardiovascular disease history\n* Active systemic infection\n* Endothelial Injury history\n* Active smoking status including vape, alcohol, drug addiction.","FEMALE","50 Years",{"count":177,"type":22},80,[179,180],"PHASE1","PHASE2","\\---\n\nWhy Is This Study Being Done?\n\nWomen who have preeclampsia during pregnancy face a much higher risk of heart disease later in life. Preeclampsia is a serious pregnancy condition that causes high blood pressure and damages blood vessels. Even after the baby is born, the blood vessels do not fully heal on their own, which can lead to heart problems\u002Fcardiovascular years later.\n\nThis study tests whether a new treatment called exosomes can help repair damaged blood vessels in women who had preeclampsia. Exosomes are tiny particles that come from stem cells and contain healing substances that may help blood vessels work better.\n\n\\---\n\nWhat Will Happen in This Study?\n\nThis study will include 80 women who recently gave birth and had preeclampsia during their pregnancy. Half of the women will receive the exosome treatment through an IV, and half will receive a placebo (a substance with no active treatment).\n\n\\---\n\nWhat Will Participants Need to Do?\n\nParticipants will:\n\n* Have blood tests and other health checks\n* Receive one treatment through an IV\n* Return for follow-up visits at 1 week after treatment\n* Have tests to check how well their blood vessels are working\n\nWho Can Join This Study?\n\nWomen who:\n\n* Recently gave birth (within 1-2 weeks)\n* Had preeclampsia during their last pregnancy\n* Are healthy enough to participate\n* Can give permission to join the study\n\nWhat Are the Possible Benefits and Risks?\n\nThe treatment may help repair blood vessel damage and reduce the risk of future heart disease. The exosome treatment appears to be safe based on other studies, but like any medical treatment, there may be side effects.\n\n\\---\n\nHow Long Will the Study Last?\n\nThe main treatment happens during one visit, with follow-up visits for 1 week to check on participants' health and see if the treatment is working.\n\nThis research may lead to new ways to protect women's heart health after pregnancy complications.",[183,184,185,186,187],"Preeclampsia","Postpartum","Endothelial Injury","Exosome Multiomics","Cell Therapy",[183,184,189,190,187],"Stem Cell","Exosome","2025-09-12",{"date":193,"type":33},"2025-09-19",{"date":195,"type":33},"2024-07-01",{"date":90,"type":22},{"name":39,"class":40},{"id":199,"slug":200,"hasResults":11,"nctId":201,"briefTitle":202,"officialTitle":203,"acronym":4,"eligibilityCriteria":204,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":205,"targetDuration":4,"studyType":23,"phases":206,"briefSummary":207,"conditions":208,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":211,"lastUpdatePostDateStruct":212,"startDateStruct":214,"completionDateStruct":216,"leadSponsor":218,"locationsCount":4},"100595629","aerobic-and-resistance-training-in-post-cabg-patients-100595629","NCT07034937","Aerobic and Resistance Training in Post-CABG Patients","Effect of Combination Aerobic and Resistance Training on Diaphragm Excursion Value and Pulmonary Functions in Post Coronary Artery Bypass Grafting Patients","Inclusion Criteria:\n\n1. Patients post-CABG surgery maximum 12 weeks after the procedure\n2. Age 40-65 years\n3. Visual and hearing health\n4. Ready to participate in research and sign informed consent.\n\nExclusion Criteria:\n\n1. Blood pressure greater than 160 mmHg for systolic and diastolic blood pressure greater than 100 mmHg\n2. Patients with contraindications to aerobic and resistance training, such as fractures that limit movement.\n3. Patients undergoing other therapies that may affect diaphragmatic muscle measurement results, such as electrical diaphragmatic stimulation.",{"count":78,"type":22},[25],"This study investigates the effect of combined aerobic and resistance training using resistance bands on diaphragmatic excursion and pulmonary function (FVC, FEV₁, PEF) in post-CABG patients undergoing phase II cardiac rehabilitation.",[209,210],"Coronary Artery Disease","Post Coronary Artery Bypass Grafting","2025-06-19",{"date":213,"type":33},"2025-06-24",{"date":215,"type":22},"2025-08-01",{"date":217,"type":22},"2026-07-30",{"name":39,"class":40},{"id":220,"slug":221,"hasResults":11,"nctId":222,"briefTitle":223,"officialTitle":224,"acronym":4,"eligibilityCriteria":225,"healthyVolunteers":11,"sex":17,"minAge":49,"maxAge":226,"enrollmentInfo":227,"targetDuration":4,"studyType":23,"phases":229,"briefSummary":230,"conditions":231,"keywords":233,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":236,"lastUpdatePostDateStruct":237,"startDateStruct":239,"completionDateStruct":241,"leadSponsor":243,"locationsCount":41},"100594182","phase-2-0005-latanoprost-gel-for-nonsegmental-vitiligo-100594182","NCT07016113","0.005% Latanoprost Gel for Nonsegmental Vitiligo","Comparison of the Effectiveness Between a Combination of 0.005% Latanoprost Gel With 308 nm Excimer Phototherapy and a Combination of 0.1% Mometasone Furoate Cream With 308 nm Excimer Phototherapy on Repigmentation of Nonsegmental Vitiligo in Children","Inclusion Criteria:\n\n* Patients with non-segmental vitiligo.\n* Patients with stable vitiligo for at least 6 months based on the Vitiligo Disease Activity (VIDA) score.\n* Aged 10-17 years.\n* Affected area \\\u003C10%.\n* Having at least two lesions to be treated. The vitiligo lesions selected for treatment must meet the following criteria:\n\n  1. Relatively the same size, ranging from a minimum of 1 cm² to 4 cm².\n  2. Bilateral location on both sides of the body.\n  3. A minimum distance of 5 cm between the studied lesions and other vitiligo lesions.\n  4. Not located on the palms, soles, or genital area.\n\nExclusion Criteria:\n\n* Use of topical therapy (corticosteroids, calcineurin inhibitors, psoralen, and antioxidants) for at least 2 weeks before the study, systemic therapy (corticosteroids, antioxidants, and vitamin D) for at least 4 weeks before the study, and phototherapy for at least 4 weeks before the study.\n* Presence of other active autoimmune diseases such as type 1 diabetes mellitus, thyroid disease, alopecia areata, rheumatoid arthritis, or Addison's disease, based on medical history and physical examination.\n* History of or current skin cancer, photosensitivity, or undergoing radiotherapy.\n* Allergy or contraindication to topical corticosteroids or latanoprost.\n* History of hypertension, asthma, diabetes mellitus, anemia, kidney, liver, neurological, or cardiovascular diseases.","17 Years",{"count":228,"type":22},10,[180],"Latanoprost, a prostaglandin F2α (PGF2α) analog used for glaucoma treatment, is known to cause iris darkening, hypertrichosis, and periocular skin hyperpigmentation. PGF2α has been shown to stimulate the growth of melanocyte dendrites, increasing dendricity even at low doses, as well as enhancing tyrosinase activity and quantity, thereby promoting repigmentation. Studies on the use of 0.005% latanoprost gel in both children and adults with vitiligo have demonstrated effective repigmentation without reported side effects.",[232],"Vitiligo - Macular Depigmentation",[234,235],"Latanoprost","Vitiligo","2025-06-03",{"date":238,"type":33},"2025-06-11",{"date":240,"type":22},"2025-07-01",{"date":242,"type":22},"2025-11-30",{"name":39,"class":40},{"id":245,"slug":246,"hasResults":11,"nctId":247,"briefTitle":248,"officialTitle":248,"acronym":4,"eligibilityCriteria":249,"healthyVolunteers":11,"sex":17,"minAge":250,"maxAge":251,"enrollmentInfo":252,"targetDuration":4,"studyType":23,"phases":254,"briefSummary":255,"conditions":256,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":258,"lastUpdatePostDateStruct":259,"startDateStruct":261,"completionDateStruct":263,"leadSponsor":265,"locationsCount":41},"100587207","phase-2-the-relationship-between-microbioma-balance-and-acne-vulgaris-as-a-new-acne-treatment-100587207","NCT06925386","The Relationship Between Microbioma Balance and Acne Vulgaris as a New Acne Treatment","Inclusion Criteria:\n\n* individuals aged 13 to 45 years\n* diagnosed with acne vulgaris by a certified dermatologist, presenting with mild to moderate facial acne based on the lesion count criteria by Lehman et al. Mild acne is defined as having fewer than 20 comedones or fewer than 15 papular\u002Fpustular lesions, while moderate acne is characterized by 20-100 comedones and 20-50 papular\u002Fpustular lesions.\n* must have experienced recurring new acne lesions in the past 6 months\n* must be willing to comply with all protocol requirements\n* must be willing to have standardized facial photograps taken using an imaging system\n* must be able to follow study and adhere to a fixed schedule\n* must have ability to provide inform concent for participation in the study\n* must be generally healthy and in good mental condition.\n\nExclusion Criteria:\n\n* pregnant patients\n* subjects who have undergone hormonal acne treatment within six months prior to the study\n* subjects who have taken oral isotretinoin within one month prior to the study.\n* simultaneous participation in a different study conducted by an external research institution at the same testing site.\n* inadequate language proficiency (both spoken and written)\n* participation in the study under the influence of alcohol and\u002For drugs, as well as substance addiction\n* severe diseases (cardiovascular, hepatic, renal, or pulmonary diseases, severe diabetes mellitus) or chronic infections (Hepatitis, HIV).\n* immunodeficiency.\n* current use of the following topical or systemic medications: corticosteroids, immunosuppressants, and antihistamines.\n* skin conditions such as vitiligo, psoriasis, or atopic dermatitis.\n* any other diseases or medications that may directly interfere with the study or pose a risk to the subject's health","13 Years","45 Years",{"count":253,"type":22},64,[180],"Background: Acne vulgaris is a chronic inflammatory condition primarily caused by Cutibacterium acnes, which disrupts skin homeostasis, thereby triggering immune responses and sebum metabolism. Dysbiosis is an imbalances in the skin and gut microbiota identified as a significant factor contributing to acne progression. Standard therapy often rely on antibiotics, but the long-term use has increased antibiotic resistance, including in Indonesia. Consequently, alternative methods, such as probiotics and mesenchymal stromal cell (MSC) secretomes are gaining attention for immunomodulatory and regenerative properties. These novel therapies have shown promising results in modulating the skin and gut microbiota while reducing inflammation.\n\nStudy Design: A phase 2 double-blind randomized controlled trial was adopted using a parallel group design with four arms, namely: (1) standard therapy with oral probiotics and topical secretome (placebo), (2) standard therapy with oral probiotics (placebo) and topical secretome, (3) standard therapy with oral probiotics and topical secretome, and (4) standard therapy with oral probiotics (placebo) and topical secretome (placebo). Sixty-four mild to moderate acne vulgaris patients were randomly allocated to these groups. Interventions were administered over a period of 8 weeks, with outcomes measured at baseline and post-therapy. This study was conducted at Dermatology and Venereology Department of Bali Mandara General Hospital (RSBM). The primary outcome is the reduction of comedones and inflammatory lesions, assessed using the Yolov8 method. Secondary outcomes include gut and skin health parameters, such as tryptophan metabolites, collagen, pH, moisture, sebum levels, and IL-6, to explore the relationship between microbiome balance, skin condition, and inflammation in acne.\n\nDiscussion: In the context of increasing antibiotic resistance in Indonesia, where therapies often fail to produce sustainable clinical outcomes, this study showed the potential of combining probiotics and MSC secretomes as adjunctive therapies for acne vulgaris. Probiotics restored gut and skin microbiota balance, while MSC secretomes promoted immune modulation and tissue repair. The results of this study paved the way for innovative, non-antibiotic methods for acne management, addressing the need for sustainable and effective therapies amidst growing concerns over dysbiosis and antibiotic resistance.",[257],"Acne Vulgaris","2025-04-06",{"date":260,"type":33},"2025-04-13",{"date":262,"type":22},"2025-05-01",{"date":264,"type":22},"2026-05-01",{"name":39,"class":40},{"id":267,"slug":268,"hasResults":11,"nctId":269,"briefTitle":270,"officialTitle":271,"acronym":4,"eligibilityCriteria":272,"healthyVolunteers":11,"sex":17,"minAge":273,"maxAge":4,"enrollmentInfo":274,"targetDuration":4,"studyType":23,"phases":276,"briefSummary":277,"conditions":278,"keywords":4,"overallStatus":60,"whyStopped":4,"lastUpdateSubmitDate":280,"lastUpdatePostDateStruct":281,"startDateStruct":283,"completionDateStruct":285,"leadSponsor":287,"locationsCount":41},"100564416","effect-of-modified-poco-poco-exercise-to-frailty-stages-expression-of-global-dna-methylation-gdf15-and-lamin-a-cop-100564416","NCT06628895","Effect of Modified Poco-Poco Exercise to Frailty Stages, Expression of Global DNA Methylation, GDF15 and Lamin A COP","Effect of Modified Poco-Poco Exercise to Frailty Stages, Expression of Global DNA Methylation, GDF15 and Lamin A COP on Elderly Living On Community in Bandung","Inclusion Criteria:\n\n1. Frailty level is in pre-frailty\n2. MoCA INA score above 18\n3. Domicile in Bandung City\n4. Willing to participate in the study after informed consent\n\nExclusion Criteria:\n\n1. There is a hearing impairment that may prevent the subject from receiving verbal instructions\n2. There is uncorrected visual impairment\n3. There are musculoskeletal disorders so that they cannot perform exercise procedures or procedures for measuring research variables\n4. Subjects received other rehabilitation programs\n5. Post-stroke with average limb muscle strength below three\n6. There are diseases that cause impaired cognition such as Alzheimer\\'s disease, traumatic head injury, Parkinson\\'s disease.\n7. There are severe joint diseases such as osteoarthritis and rheumatoid arthritis that may worsen during exercise or may cause difficulty in carrying out the exercise program.\n8. Severe cardiovascular disease as assessed by a heart and vascular specialist\n9. Unable to attend Exercises regularly","60 Years",{"count":275,"type":22},17,[25],"The goal of this clinical trial is to know the effect of multicomponent exercise in frail elderly in community to aging hallmarks. The main question\\[s\\] it aims to answer are:\n\n1. Do global DNA methylation levels change in elderly people in Bandung after receiving modified poco-poco exercise?\n2. Do GDF15 levels change in elderly people in Bandung after they are given modified poco-poco exercise?\n3. Do lamin A COP levels change in elderly people in Bandung after they are given modified poco-poco exercise?\n4. Does the level of frailty in elderly people in Bandung change after they are given modified poco-poco exercise?\n\nParticipants will be asked to do flexibility, balance, aerobic and strengthening exercise included in poco-poco modified exercise three times a week for 12 weeks",[279],"Frail Elderly","2025-02-27",{"date":282,"type":33},"2025-03-04",{"date":284,"type":33},"2024-09-15",{"date":286,"type":22},"2025-04-30",{"name":39,"class":40},{"id":289,"slug":290,"hasResults":11,"nctId":291,"briefTitle":292,"officialTitle":293,"acronym":4,"eligibilityCriteria":294,"healthyVolunteers":11,"sex":17,"minAge":50,"maxAge":76,"enrollmentInfo":295,"targetDuration":4,"studyType":23,"phases":297,"briefSummary":298,"conditions":299,"keywords":303,"overallStatus":60,"whyStopped":4,"lastUpdateSubmitDate":307,"lastUpdatePostDateStruct":308,"startDateStruct":310,"completionDateStruct":312,"leadSponsor":314,"locationsCount":41},"100577142","phase-1-recovery-times-of-half-dose-sugammadex-and-neostigmine-for-rocuronium-induced-neuromuscular-blockade-100577142","NCT06794450","Recovery Times of Half Dose Sugammadex and Neostigmine for Rocuronium-induced Neuromuscular Blockade","Comparison of Recovery Times Between 1 mg\u002Fkg Sugammadex and 60 mcg\u002Fkg Neostigmine for Moderate Neuromuscular Blockade Induced by Rocuronium in Patients Undergoing Laparoscopic Cholecystectomy: A Randomized Controlled Trial","Inclusion Criteria:\n\n* Patients who underwent laparoscopic cholecystectomy under general anesthesia\n* Using muscle relaxant rocuronium\n* Aged 18-59 years\n* American Society of Anesthesiologists (ASA) physical status classification of 1 or 2.\n\nExclusion Criteria:\n\n* History of drug allergies to the agents used\n* Renal dysfunction\n* Musculoskeletal disorders\n* Central nervous system disorders\n* Difficult airways requiring intubation without the use of muscle relaxants.",{"count":296,"type":22},60,[179,180],"In operating procedure with general anesthesia muscle relaxant is usually used to increase success rate of the operation and to give better outcome. The use of reversal drugs aims to reduce the risk of post-operative complications due to muscle relaxants. Neostigmine is commonly used as a reversal drug, but its indirect mechanism of action results in a long and unpredictable recovery time. Sugammadex directly bind and inactivate rocuronium, in which resulting in a faster and predictable recovery time. However, the high price limits the use of sugammadex.\n\nThis study aims to compare the effect of half dose sugammadex and neostigmine against the moderate neuromuscular blockade of rocuronium.\n\nThe main questions it aims to answer are:\n\nDoes half dose sugammadex gives faster recovery time? Researchers will compare sugammadex to neostigmine to see if sugammadex gives faster recovery time.\n\nParticipants will:\n\nBe given sugammadex or neostigmine as a reversal drug after the operation done",[300,301,302],"Neuromuscular Blocking Agents","Reversal of Neuromuscular Blockade","Recovery Time",[304,305,306],"Sugammadex","Neostigmine","recovery time from neuromuscular blockade","2025-01-25",{"date":309,"type":33},"2025-01-28",{"date":311,"type":33},"2024-11-05",{"date":313,"type":22},"2025-02",{"name":39,"class":40},{"id":316,"slug":317,"hasResults":11,"nctId":318,"briefTitle":319,"officialTitle":320,"acronym":4,"eligibilityCriteria":321,"healthyVolunteers":11,"sex":174,"minAge":50,"maxAge":322,"enrollmentInfo":323,"targetDuration":4,"studyType":23,"phases":324,"briefSummary":326,"conditions":327,"keywords":329,"overallStatus":60,"whyStopped":4,"lastUpdateSubmitDate":330,"lastUpdatePostDateStruct":331,"startDateStruct":333,"completionDateStruct":335,"leadSponsor":337,"locationsCount":41},"100563623","phase-2-safety-of-administering-isoniazid-to-sle-patients-to-prevent-tb-100563623","NCT06618573","Safety of Administering Isoniazid to SLE Patients to Prevent TB","Study on the Safety of Administering Isoniazid to Systemic Lupus Erythematosus Patients to Prevent Tuberculosis","Inclusion Criteria:\n\nSLE patients with conditions of :\n\n* No signs and symptoms of active TB\n* Not under TB treatment\n* No History of TB, malignancy, HIV, liver function test abnormality\n* Not in pregnancy\u002Flactation\n* No other active infections\n* Remission or low to moderate disease activity state\n* Consented to join the study completely\n\nExclusion Criteria:\n\nSLE patients with conditions of :\n\n* History of allergy to Isoniazid\n* Chronic liver disease, including chronic hepatitis B or C virus\n* Malignancy\n* Pregnancy","55 Years",{"count":296,"type":22},[180,325],"PHASE3","Systemic Lupus Erythematosus (SLE) is a prototypical systemic autoimmune disease characterized by heterogeneity, multisystem involvement, and production of multiple autoantibodies. Clinical features can vary, from mild skin and joint involvement to severe and life-threatening conditions.\n\nPatients with lupus are more susceptible to infections, in addition to being immunocompromised, and due to the administration of corticosteroid and cytotoxic drugs. The presence of these infections is a cause of death in lupus disease in addition to the activity of the disease itself, especially in Asia-Pacific countries. One infection that often occurs in lupus is Tuberculosis (TB).\n\nEfforts have been made to prevent TB infection in vulnerable populations, including isoniazid (INH) prophylaxis. In 2010, World Heatlh Organization issued guidelines for HIV patients to receive INH prophylaxis to prevent TB infection. The implementation of Isoniazid Preventive Therapy (IPT) is quite cheap using INH with mild side effects.18 A meta-analysis study of INH prophylaxis in patients with HIV found that the efficacy of this prophylaxis significantly reduced TB incidence by 35% with an RR of 0.65%. In addition, INH was found to be safe, with no significant increase in drug reactions, according to a meta-analysis of prophylaxis studies in HIV patients.\n\nHowever, there is no guideline for INH prophylaxis for SLE patients, as there is for HIV patients, due to lack of data on this issue.\n\nStudies on the effectiveness of INH prophylaxis on the prevention of TB infection for SLE patients should be conducted, but before that, studies on the safety of INH therapy in SLE patients should be conducted.",[152,328],"Systemic Lupus Erythematosus",[152,328],"2024-09-26",{"date":332,"type":33},"2024-10-01",{"date":334,"type":33},"2022-08-15",{"date":336,"type":22},"2025-12-01",{"name":39,"class":40},{"id":339,"slug":340,"hasResults":11,"nctId":341,"briefTitle":342,"officialTitle":343,"acronym":4,"eligibilityCriteria":344,"healthyVolunteers":11,"sex":17,"minAge":345,"maxAge":273,"enrollmentInfo":346,"targetDuration":4,"studyType":23,"phases":348,"briefSummary":349,"conditions":350,"keywords":354,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":358,"lastUpdatePostDateStruct":359,"startDateStruct":361,"completionDateStruct":362,"leadSponsor":364,"locationsCount":4},"100561236","phase-2-effectivity-of-protein-purified-derivative-treatment-for-anogenital-warts-in-hiv-patient-100561236","NCT06587542","Effectivity of Protein Purified Derivative Treatment for Anogenital Warts in HIV Patient","Comparison of the Response and Pathomechanism of Purified Tuberculin Unit Protein Injection Therapy for Anogenital Warts with and Without HIV Infection","Inclusion Criteria:\n\n1. Anogenital warts whose diagnosis is made based on anamnesis and physical examination, before receiving intralesional purified protein derivative injection therapy.\n2. All stored biological materials that have been previously taken through tissue from anogenital warts patients whose diagnosis was confirmed based on history and physical examination, 3 weeks after receiving the first intralesional purified protein derivative injection therapy.\n\nExclusion Criteria:\n\n* 1\\. With a history of allergies to purified protein derivative, generalized dermatitis, asthma and skin allergies 2. Currently taking immunosuppressant or immunomodulatory drugs based on the history and clinical examination.\n\n  3\\. Have an immunodeficiency disease based on anamnesis and clinical examination, except for HIV based on anamnesis, clinical examination and serological examination (anti-HIV).\n\n  4\\. Have a history of suffering from malignancy based on history and clinical examination.\n\n  5\\. Infected with tuberculosis based on history, clinical examination and chest radiography.\n\n  6\\. Infected with other STIs based on history, clinical examination, and serological examination (venereal disease research laboratory (VDRL), Treponema pallidum hemagglutination assay (TPHA), and Hepatitis B surface antigen (HBsAg)).","15 Years",{"count":347,"type":22},30,[180,325],"Warts are a common viral infection of the skin and are prevalent throughout the world, with an overall prevalence in the United States estimated at 2-20%. The incidence of anogenital warts occurs more frequently in HIV-infected patients, with a seven-fold increase in risk compared to patients without HIV infection. Available treatments for anogenital warts can only reduce, but cannot eradicate, HPV infection. There are many therapeutic options for treating anogenital warts, but none can prevent recurrence. Immunotherapy has become one of the best therapeutic options for warts caused by HPV infection because it increases the immune response to HPV infection, resulting in remission, both in lesions that receive direct and indirect intralesional therapy. Immunotherapy, acts as a basic principle to enhance cell-mediated immunity for wart clearance. Apart from low recurrence, regression in immunotherapy for warts due to HPV infection generally occurs without cicatrices, so it is a consideration in choosing therapy, including anogenital warts. Various types of immunotherapy have been used, one of which is purified protein derivative, which can be used as an alternative therapy option for anogenital warts. In a previous case report, even though an HIV patient had an abnormal immune system, tuberculin protein purified derivative therapy, immunotherapy provided a significant clinical response in the form of a reduction in lesion size, compared to patients who were not given therapy. Research regarding the comparison of the response to tuberculin protein purified derivative therapy in anogenital warts patients with and without HIV infection has never been reported. Therefore, researchers are interested in examining the comparison of the response to tuberculin purified protein derivative therapy in anogenital warts patients between those with and without HIV infection and knowing the comparison of local and systemic cytokine changes when administering anogenital wart therapy with tuberculin protein purified derivative between those with and without HIV infection.",[351,352,353],"Anogenital Warts","HIV Infection","Tuberculin Purified Protein Derivative",[355,356,357],"anogenital warts","HIV infection","tuberculin purified protein derivative","2024-09-16",{"date":360,"type":33},"2024-09-19",{"date":284,"type":22},{"date":363,"type":22},"2025-12-31",{"name":39,"class":40},{"id":366,"slug":367,"hasResults":11,"nctId":368,"briefTitle":369,"officialTitle":369,"acronym":4,"eligibilityCriteria":370,"healthyVolunteers":11,"sex":17,"minAge":50,"maxAge":4,"enrollmentInfo":371,"targetDuration":372,"studyType":53,"phases":4,"briefSummary":373,"conditions":374,"keywords":378,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":382,"lastUpdatePostDateStruct":383,"startDateStruct":384,"completionDateStruct":385,"leadSponsor":387,"locationsCount":41},"100561237","correlations-between-symptoms-of-anxiety-andor-depression-with-dysphagia-severity-level-100561237","NCT06587555","Correlations Between Symptoms of Anxiety And\u002For Depression with Dysphagia Severity Level","Inclusion Criteria:\n\n1. Participants aged 18 years and above.\n2. Individuals diagnosed with dysphagia by a qualified healthcare professional\n3. Participants with documented anxiety and\u002For depression symptoms were assessed using standardized psychological assessments\n4. Willing to participate\n\nExclusion Criteria:\n\n1. Participants who have MOCA INA \\\u003C 18\n2. Participants with severe malnutrition, showed by BMI WHO Asia Pacific \\\u003C 18.5\n3. Participants with unstable hemodynamics, GCS \\\u003C 15\n4. Participants who had a history of diagnosed anxiety and \u002F or depression\n5. Participants who had a history of using an antipsychotic drug",{"count":347,"type":22},"1 Month","The goal of this observational study is to know any CORRELATIONS BETWEEN SYMPTOMS OF ANXIETY AND \u002F OR DEPRESSION WITH DYSPHAGIA SEVERITY LEVEL in is all of the new or ongoing patients with dysphagia in the Neurorehabilitation Department at Hasan Sadikin General Hospital Bandung and who meet the inclusion and exclusion criteria. The main questions it aims to answer are:\n\nHypothesis 1 H0 : There is no correlation between increased severity of dysphagia and higher levels of anxiety symptoms H1 : There is a correlation between increased severity of dysphagia and higher levels of anxiety\n\nHypothesis 2 H0 : There is no correlation between increased severity level of dysphagia and higher level of depression symptoms H1 : There is a correlation between increased severity of dysphagia and higher levels of depression\n\nHypothesis 3 H0 : There is no correlation between increased severity level of anxiety and dysphagia and higher level of depression symptoms H1 : There is a correlation between increased severity of anxiety and dysphagia and higher levels of depression",[375,376,377],"Dysphagia","Anxiety","Depression",[379,376,377,380,381],"Dysphagia Severity Level","Dyspahgia","HADS","2024-09-04",{"date":360,"type":33},{"date":332,"type":22},{"date":386,"type":22},"2025-03-01",{"name":39,"class":40},{"id":389,"slug":390,"hasResults":11,"nctId":391,"briefTitle":392,"officialTitle":392,"acronym":4,"eligibilityCriteria":393,"healthyVolunteers":11,"sex":17,"minAge":50,"maxAge":4,"enrollmentInfo":394,"targetDuration":395,"studyType":53,"phases":4,"briefSummary":396,"conditions":397,"keywords":401,"overallStatus":60,"whyStopped":4,"lastUpdateSubmitDate":405,"lastUpdatePostDateStruct":406,"startDateStruct":408,"completionDateStruct":410,"leadSponsor":412,"locationsCount":41},"100560253","use-of-surface-electromyography-as-a-tools-to-predict-upper-extremity-recovery-function-after-stroke-100560253","NCT06574737","Use of Surface Electromyography as a Tools to Predict Upper Extremity Recovery Function After Stroke","Inclusion Criteria:\n\n1. Patients who are hospitalized with upper extremity weakness due to stroke on the same side which confirmed with computed tomography (CT) scan or structural magnetic resonance imaging (MRI), in the acute phase\n2. Men and women aged more than 18 years old\n3. Willing to participate\n\nExclusion Criteria:\n\n1. Cognitive impairment (MoCA-Ina score less than 26)\n2. Impaired consciousness (GCS score less than 15)\n3. Unstable medical conditions at time of hospitalization\n4. Patients with pacemaker\n5. Having other injury or dysfunction in the impaired side of upper extremity that caused restrictions on the range of joint movement and muscle weakness, such as fractures, periarthritis, or moderate-severe pain\n6. Diagnosis of other neurological disease or disorders in addition to stroke (e.g., traumatic brain injury, neuropathy or radiculopathy)\n7. Get treated in isolation room\n8. Hypersensitivity to gel electrodes",{"count":347,"type":22},"3 Months","Hypothesis :\n\nBased on the framework and premises above, the hypothesis is formulated as follows: H0 : surface electromyography parameters cannot predicts upper extremity motor function recovery in stroke patients H1: surface electromyography parameters can predicts upper extremity motor function recovery in stroke patients",[398,399,400],"Upper Extremity Paresis","Muscle Contracture Upper Arm","Stroke",[402,403,404],"Surface electromyography","Predictor Stroke","Upper Extremity Recovery","2024-08-27",{"date":407,"type":33},"2024-08-29",{"date":409,"type":33},"2024-05-01",{"date":411,"type":22},"2025-07-31",{"name":39,"class":40},{"id":414,"slug":415,"hasResults":11,"nctId":416,"briefTitle":417,"officialTitle":418,"acronym":419,"eligibilityCriteria":420,"healthyVolunteers":11,"sex":17,"minAge":50,"maxAge":4,"enrollmentInfo":421,"targetDuration":4,"studyType":23,"phases":423,"briefSummary":424,"conditions":425,"keywords":4,"overallStatus":60,"whyStopped":4,"lastUpdateSubmitDate":427,"lastUpdatePostDateStruct":428,"startDateStruct":430,"completionDateStruct":432,"leadSponsor":434,"locationsCount":41},"100388692","phase-2-dexamethasone-for-cerebral-toxoplasmosis-100388692","NCT04341155","Dexamethasone for Cerebral Toxoplasmosis","Adjunctive Dexamethasone for Cerebral Toxoplasmosis: a Double-blinded Randomized Controlled Trial","De-Tox","Inclusion Criteria:\n\n1. Age 18 years or above.\n2. Clinical signs and symptoms compatible to cerebral toxoplasmosis\n3. Serology HIV positive\n4. Immunoglobulin G anti-toxoplasma titre is positive\n5. One or more mass lesions on the neuroradiological finding\n6. None or less than 3 days of dexamethasone therapy taken\n7. Written informed consent from the patients or from close relatives of the patient if the patient is unconscious.\n\nExclusion Criteria:\n\n1. History of anti-toxoplasmosis administrattion for more than 5 days before recruitment\n2. Hypersensitivity or other contraindication to dexamethasone\n3. Pregnancy",{"count":422,"type":22},138,[180],"Toxoplasma gondii infects over one third of the global human population. Cerebral toxoplasmosis is the most common opportunistic infection in HIV patients resulting in up to 50% of mortality with proper treatment and 80% without it. The fatality mainly due to the brain edema resulted from the mass effect lesion. In addition of anti toxoplasmosis given, adjunctive therapy such as steroid is recommended in order to reduce brain edema, but the dose and duration of administration in cerebral toxoplasmosis has not been evaluated in a clinical trial. Adjunctive therapy given in cerebral toxoplasmosis patients still remains unclear. Moreover, its safety in immunodeficiency cases is still debatable.",[426],"Toxoplasmosis, Cerebral","2024-07-02",{"date":429,"type":33},"2024-07-03",{"date":431,"type":33},"2021-04-16",{"date":433,"type":22},"2025-07",{"name":39,"class":40},{"id":436,"slug":437,"hasResults":11,"nctId":438,"briefTitle":439,"officialTitle":440,"acronym":4,"eligibilityCriteria":441,"healthyVolunteers":11,"sex":17,"minAge":50,"maxAge":4,"enrollmentInfo":442,"targetDuration":4,"studyType":23,"phases":444,"briefSummary":445,"conditions":446,"keywords":449,"overallStatus":60,"whyStopped":4,"lastUpdateSubmitDate":455,"lastUpdatePostDateStruct":456,"startDateStruct":458,"completionDateStruct":460,"leadSponsor":462,"locationsCount":41},"100429562","effectiveness-of-ecp-therapy-in-stable-angina-pectoris-patients-100429562","NCT04873687","Effectiveness of ECP Therapy in Stable Angina Pectoris Patients","Effectiveness of External Counter Pulsation (ECP) Therapy in Stable Angina Pectoris Patients; a Proof of Principal Clinical Trial","Inclusion Criteria:\n\n* Age \\>= 18 years old\n* Diagnosed with stable angina pectoris\n* Anatomic vessel disease (VD) lesion with 2VD\u002F3VD\n* Indicated for CABG and in waiting list of CABG procedure; or refuse for CABG and choose medical therapy only; or patients who are decided by the responsible doctor for medical treatment alone because of the high risks of CABG surgery.\n* Not planned to urgent CABG\n* Minimum optimal medical therapy within 2 weeks\n* Able and willing to sign informed consent and comply with study procedures\n* The patient lives in Bandung City and its neighborhood\n* Retired patient; or not actively working during working hours; or willing to take the time to participate in research.\n\nExclusion Criteria:\n\n* Congestive Heart Failure\n* Chronic heart failure with Functional Class NYHA III - IV\n* LVEF \\\u003C35%\n* Unprotected left main stenosis \\>50%\n* Blood pressure \\>180\u002F110mmHg\n* Acute coronary syndrome\n* Acute Heart Failure\n* Severe aorta regurgitation\n* Malignant arrhythmia\n* Atrial fibrillation\n* Premature ventricular complex\n* Peripheral occlusive artery disease\n* Phlebitis\n* Deep vein thrombosis\n* Hemorrhagic diathesis\n* Severe chronic kidney disease\n* Aortic aneurysm\n* Abdominal aneurysm\n* Osteoarthritis\n* Low back pain\n* Pregnancy\n* Registered as other clinical study participant",{"count":443,"type":22},84,[25],"External Counterpulsation (ECP) is a non-invasive therapy using pressured cuff that is performed on patients with refractory stable angina pectoris to relieve symptoms and increase quality of life. In Indonesia, waiting time for getting coronary artery bypass grafting (CABG) procedure for revascularization treatment in stable angina pectoris patients is way longer than international recommendation which correlates with increase morbidity and mortality during the waiting time. Utilization of ECP for such patients who wait for CABG procedure is still unclear. The investigator aim to evaluate efficacy of addition of ECP compared with medical therapy alone for this population. The efficacy is evaluated using measurement from echocardiography result, treadmill test result, and clinical outcome. if applicable, examination of myocardial perfusion using nuclear examination will also be performed.",[447,448],"Counterpulsation","Angina Pectoris",[450,451,452,453,454],"External Counterpulsation","Stable Angina Pectoris","Indicated CABG","Global longitudinal strain","Ischemic response","2023-09-21",{"date":457,"type":33},"2023-09-25",{"date":459,"type":33},"2023-07-01",{"date":461,"type":22},"2026-12",{"name":39,"class":40},""]